Heron Therapeutics, Inc. — Q3 2019 Form 10-Q Summary
Business Context and Reporting Period
Heron Therapeutics is a commercial-stage biotechnology company developing treatments for chemotherapy-induced nausea and vomiting and postoperative pain. The filing covers the three and nine months ended September 30, 2019, compared with the corresponding 2018 periods. Heron marketed SUSTOL and CINVANTI in the United States and was preparing HTX-011 for potential approval and commercialization.
Key Financial Metrics
| Metric | Q3 2019 | Q3 2018 | Nine Months 2019 | Nine Months 2018 |
|---|---|---|---|---|
| Net product sales | $42.6 million | $19.8 million | $110.9 million | $48.6 million |
| Cost of product sales | $17.2 million | $7.6 million | $45.7 million | $15.9 million |
| Gross margin | 59.6% | 61.7% | 58.7% | 67.2% |
| Operating loss | $(34.9) million | $(41.8) million | $(151.3) million | $(132.6) million |
| Net loss | $(33.6) million | $(38.3) million | $(146.8) million | $(129.3) million |
| Net loss per share | $(0.42) | $(0.49) | $(1.85) | $(1.81) |
| Net cash used in operating activities | Not provided for quarter | Not provided for quarter | $(97.6) million | $(158.3) million |
Q3 operating margin was approximately negative 81.8%, compared with negative 211.2% in the prior-year quarter. Nine-month operating margin was approximately negative 136.5%, compared with negative 272.8% in 2018. The improvement in margin percentages primarily reflected substantially higher product sales, although Heron remained unprofitable.
- Product mix: CINVANTI sales were $36.4 million in Q3 and $97.6 million for the first nine months, compared with $16.4 million and $32.8 million, respectively, in 2018. SUSTOL sales were $6.2 million in Q3 and $13.3 million year to date, compared with $3.4 million and $15.8 million in 2018.
- Operating expenses: Research and development expense was $34.7 million in Q3 and $119.1 million year to date. Sales and marketing expense was $17.0 million in Q3 and $69.3 million year to date. The increases were driven principally by HTX-011 development and launch-preparation activities, personnel costs and stock-based compensation.
- Unusual items: Cost of product sales included $1.7 million in Q3 and $3.3 million year to date for write-offs of short-dated SUSTOL inventory. Year-to-date sales and marketing expense included $8.4 million of stock-based compensation related to the retirement of the former President.
- Cash flow: Operating cash use declined to $97.6 million from $158.3 million, primarily due to working-capital changes associated with the prior-year CINVANTI launch and higher noncash stock compensation.
- Investing cash flow: Investing activities provided $104.6 million, principally reflecting net maturities of short-term investments, compared with $286.9 million of cash used in 2018 for net investment purchases.
- Financing cash flow: Financing activities provided $21.3 million, including $20.2 million from stock-option exercises, compared with $354.5 million in 2018, when Heron completed two major equity offerings.
Balance Sheet, Debt and Liquidity
| Balance Sheet Item | September 30, 2019 | December 31, 2018 |
|---|---|---|
| Cash and cash equivalents | $60.1 million | $31.8 million |
| Short-term investments | $196.2 million | $300.5 million |
| Cash, cash equivalents and short-term investments | $256.3 million | $332.4 million |
| Total assets | $393.0 million | $462.2 million |
| Total liabilities | $107.5 million | $92.0 million |
| Stockholders’ equity | $285.4 million | $370.2 million |
Heron had $256.3 million of cash, cash equivalents and short-term investments at September 30, 2019. In October 2019, it sold 9.9 million shares for net proceeds of $162.2 million, producing pro forma liquidity of approximately $418.5 million. Management stated that existing liquidity, including the offering proceeds, was expected to fund anticipated requirements for at least one year from the filing date.
The company had $7.1 million of principal outstanding under secured related-party Convertible Notes, reported at a $5.4 million carrying value after discount. The notes bear interest at 6%, mature in May 2021, may be subject to holder-requested prepayment, and were convertible into approximately 8.9 million shares. The notes are secured by substantially all company assets and impose restrictions on certain financing and corporate actions. Heron reported compliance with all covenants.
Material Changes, Guidance and Outlook
- Revenue more than doubled year over year in both the quarter and nine-month period, driven primarily by CINVANTI growth. However, the nine-month net loss increased because research, development, commercial launch and personnel-related spending grew faster than revenue.
- Effective October 1, 2019, Heron discontinued all discounting of SUSTOL and warned that SUSTOL net sales would be significantly lower in future periods.
- Generic versions of ALOXI and EMEND IV entered the market, increasing competitive pressure on SUSTOL and CINVANTI.
- The FDA issued a Complete Response Letter for HTX-011 on April 30, 2019, citing additional Chemistry, Manufacturing and Controls and non-clinical information. The FDA did not identify clinical safety or efficacy issues and did not require additional clinical studies or data analyses.
- In October 2019, the FDA accepted Heron’s HTX-011 NDA resubmission and set a PDUFA goal date of March 26, 2020. The EMA review was ongoing, with an opinion anticipated in the first half of 2020.
- CINVANTI received an FDA supplement approval in October 2019 to add a 130 mg single-dose regimen for patients receiving moderately emetogenic chemotherapy. Earlier in 2019, the FDA had approved a two-minute injection administration option.
- Management provided no specific revenue, earnings or product-sales guidance in the filing. It expected continued substantial losses and negative operating cash flow while funding product development, regulatory activities and commercialization.
Risks, Contingencies and Unusual Items
- Heron had an accumulated deficit of $1.1 billion and stated that it expected to continue incurring substantial losses.
- Product revenue depends heavily on CINVANTI and SUSTOL market acceptance, pricing, reimbursement, discounting, competition, manufacturing capacity and third-party distribution.
- HTX-011 remained subject to regulatory uncertainty despite the accepted resubmission, and approval was not assured.
- Three major customers represented 98.0% of Q3 net product sales, 97.8% of nine-month sales and 99.0% of accounts receivable at September 30, 2019, creating significant customer concentration.
- A purported federal securities class action was filed against Heron and two executives concerning the decline in the company’s market value after the HTX-011 Complete Response Letter. The case was at an early stage, and the company could not estimate potential losses.
- Inventory valuation, product returns, rebates, Medicaid rebates, pricing allowances and clinical accruals involve significant estimates and could materially affect results.
- Heron relies on third-party manufacturers and suppliers, including single-source suppliers for certain components, exposing it to supply, quality, scaling and regulatory risks.
- The company adopted the new lease standard on January 1, 2019, recognizing $12.2 million of right-of-use lease assets and $12.5 million of lease liabilities at September 30, 2019; management reported no material effect on operations or liquidity.
- Disclosure controls and procedures were assessed as effective at the reasonable assurance level, with no reported material changes to internal control over financial reporting during the quarter.
Facts Investors Should Verify
- Whether CINVANTI sales growth can offset generic competition and the planned discontinuation of SUSTOL discounting.
- The FDA’s action on HTX-011 by the March 26, 2020 PDUFA goal date and the status of remaining CMC and non-clinical requirements.
- Actual cash burn and remaining liquidity after the October 2019 equity offering, including spending on HTX-011 commercialization.
- The magnitude and timing of any additional SUSTOL inventory write-offs, product returns, rebates or pricing adjustments.
- The outcome and potential financial exposure from the securities class action.
- The dilution and control implications of the Convertible Notes, which could convert into approximately 8.9 million common shares, as well as future equity financing needs.